Depression and the Nervous System: Is It More Than a Chemical Imbalance?

Where the Chemical Imbalance Story Came From

The idea has a specific origin, and knowing it explains why it was never as solid as it sounded.

In the 1950s and 1960s, two classes of drug were found to shift mood, and both affected monoamine neurotransmitters — serotonin, noradrenaline, dopamine. Researchers reasoned backwards: if raising these chemicals lifts depression, perhaps depression is a deficiency of them. That is the monoamine hypothesis, and it was a reasonable inference from what was available at the time.

It was always an inference. Reasoning from a drug's effect to a disease's cause is a known trap — paracetamol relieves headache without headache being a paracetamol deficiency. By the 1990s the hypothesis had nonetheless hardened into public shorthand, helped considerably by pharmaceutical advertising, and "a chemical imbalance in the brain" became the standard explanation given in consulting rooms and on leaflets.

So the first honest thing to say is that the story most people were told was a simplification of a hypothesis, presented with more confidence than the evidence ever supported.

What the 2022 Umbrella Review Actually Found

In July 2022 a team led by Joanna Moncrieff published an umbrella review in Molecular Psychiatry gathering the main strands of serotonin research. An umbrella review is a review of existing reviews and meta-analyses — a summary of the summaries.

They looked at five areas, and reported the following.

Their conclusion, stated plainly: the main areas of serotonin research provide no consistent evidence of an association between serotonin and depression, and no support for the hypothesis that depression is caused by lowered serotonin activity or concentrations.

And What It Was Immediately Criticised For

Most coverage stopped at the paragraph above. The scientific response was substantial and deserves equal space.

A comment authored by Sameer Jauhar, Carmine Pariante and 34 other researchers set out several objections. That the review summarised reported results rather than re-analysing data, departing from standard umbrella-review practice. That it included selected individual studies, which undercuts the point of an umbrella review. That its quality-grading criteria were set by the authors and started studies at a low rating, with thresholds such as sample size that are unrealistic for imaging and experimental work.

On substance, two objections matter most. The critics argue that tryptophan depletion studies are among the stronger evidence for serotonin involvement — lowering tryptophan lowers serotonin and can provoke depressive symptoms in people with a history of depression — and that the review downplayed this by focusing on healthy volunteers. And they argue the receptor imaging literature was read too simply, ignoring receptor pharmacology and replicated findings.

They also make a framing point worth keeping: the serotonin theory, in its scientific form, was never the claim that depression is a simple chemical imbalance. It was one proposed piece of the picture, partly offered to explain how some drugs might work.

The defensible conclusion sits between the two camps: serotonin deficiency as the cause of depression is not supported. That is not the same as showing serotonin has nothing to do with it.

The Part That Got Lost: This Is Not About Whether Antidepressants Work

This is the most consequential misreading of the whole episode, and it is worth being emphatic about.

Whether a drug works and why it works are separate questions, answered by different kinds of study. Aspirin was in use for roughly a century before its mechanism was understood; the uncertainty never made it ineffective. Antidepressant efficacy is established by randomised controlled trials, not by the serotonin hypothesis, and those trials are unaffected by the umbrella review.

The largest analysis of them, a network meta-analysis published in The Lancet in 2018, pooled 522 double-blind randomised trials covering 116,477 adults with moderate to severe depression across 21 antidepressants. All 21 were more likely than placebo to produce a treatment response at eight weeks, with odds ratios ranging from 1.37 for the least effective to 2.13 for the most.

The caveats belong here too, because they are part of the honest picture. The authors described the effects as modest and noted that non-response will occur. Of the 522 trials, 380 were judged at possible risk of bias, largely on unclear reporting of randomisation, and 46 at high risk. The analysis covered eight weeks, not years, and did not compare drugs against psychological therapy.

So: modest, real, and variable. Not a miracle, and not a myth.

The practical instruction that follows is simple. If you are taking an antidepressant, a news story about serotonin is not a reason to stop. Stopping abruptly can produce withdrawal symptoms that are unpleasant and sometimes prolonged, and relapse risk is a real consideration. Any change belongs in a conversation with the clinician who prescribed it.

So What Does Cause Depression?

The unsatisfying and well-supported answer is that no single thing does. Here is where the main strands currently stand.

Read across that table and the shape of the current model becomes clear. Depression looks less like one disease with one broken part and more like a common endpoint that several different routes arrive at — which is also why two people with the same diagnosis can need quite different things.

The Inflammation Strand, Specifically

This is the strand most often oversold in wellness writing, so it is worth the actual numbers.

A meta-analysis in Psychological Medicine pooled 37 studies covering 13,541 people with depression and 155,728 controls. It found that 27% of depressed patients had CRP above 3 mg/L — the conventional threshold for low-grade inflammation — and 58% had CRP above 1 mg/L. Compared with matched controls, the odds of raised CRP were higher in both cases, with odds ratios around 1.46.

What that supports: inflammation is genuinely part of the picture for a meaningful minority of people, and the idea deserves the research attention it is getting.

What it does not support: that depression is an inflammatory disease, that anti-inflammatory diets treat it, or that a CRP test tells you what to do. Roughly three-quarters of people with depression do not have low-grade inflammation by that threshold, the direction of causation is unresolved, and trials of anti-inflammatory treatment have produced mixed results.

What Is Replacing It: The Neuroplasticity Framework

If the serotonin deficit story is retiring, something has to take its place, and there is a leading candidate worth knowing about.

A 2024 review in Molecular Psychiatry set out what its authors call a neuroplasticity framework. The proposal is that depression is better understood not as a missing chemical but as inflexibility in the circuits handling thought and emotion — networks that have settled into a persistent negativity bias and lost the capacity to update. On this account, effective treatments work by restoring the brain's ability to change: synapses, networks and behaviour become modifiable again, and more adaptive processing follows.

The framework has an appealing feature. It explains why treatments with wildly different mechanisms — conventional antidepressants, ketamine, psychedelics in trials, psychotherapy, and neuromodulation — can all produce improvement. If what they share is enhancing plasticity rather than topping up a specific molecule, the diversity stops being puzzling. The authors are explicit that serotonergic antidepressants are efficacious, and that their framework has to account for that rather than explain it away.

Two honest notes. This is a proposed organising framework, not a settled finding, and it inherits the same problem as its predecessor: a model that explains everything can be hard to test. And "plasticity" in a research paper means measurable synaptic and network change — it is not the same thing as the word used in wellness marketing, where it tends to mean that any pleasant activity rewires your brain.

Where the Nervous System Comes Into It

The reason this topic sits in a series about the nervous system is that two of the better-supported strands are ones a person can actually observe in themselves.

Stress. Prolonged activation changes the circuitry that regulates mood and threat response — more reactivity, less top-down control. That literature, with its caveats, is in what chronic stress does to the brain, and the broader question of what regulation means in nervous system regulation.

Sleep. One night of lost sleep measurably degrades the prefrontal control of emotional reactivity. Over months, disrupted sleep is both a risk factor for depression and one of its symptoms, which is the kind of loop that sustains itself. We cover why that deficit is so hard to notice in why rest is a biological need.

Neither of these is a cause of depression in the sense the chemical imbalance story promised. Both are things that influence the system, are modifiable, and are worth attention regardless of which model eventually wins.

Why the Story You Believe Changes What You Do

There is a practical reason this is not merely an academic dispute.

The umbrella review's authors make the point themselves in their discussion: believing that depression is a chemical imbalance affects decisions about whether to start medication and whether to continue it, and may contribute to very long-term use. A person who believes they have a permanent deficiency reasons differently about stopping than a person who believes they are in a treatable episode with several contributing causes.

The reverse error is equally costly. Someone who concludes from a headline that depression is "not biological" may discount treatments that would help them, or hear their own condition reframed as a failure of effort. Neither framing is accurate, and both change behaviour.

The accurate version is less tidy and more useful: depression is a real condition with multiple contributing routes, several effective treatments whose mechanisms are incompletely understood, and a meaningful role for things like sleep, activity and circumstances that nobody has to wait for a mechanism to act on.

What Follows Practically

Four things are reasonable regardless of how the mechanism debate resolves.

• Treat the condition, not the theory. Psychological therapies and medication both have substantial trial evidence. Which to try, in what order, is a clinical conversation, and the uncertainty about mechanism is not a reason to delay it.
• Protect sleep. It is one of the few levers with a two-way relationship to depression and it responds to deliberate effort.
• Move regularly. Exercise has the most consistent evidence of any lifestyle intervention for depressive symptoms, and a BMJ network meta-analysis of 218 trials found walking, jogging, yoga and strength training all effective.
• Rule out the mimics. Thyroid disease, anaemia, sleep apnoea, vitamin deficiencies and several medications produce symptoms that look like depression and have specific treatments. A blood test is cheap.

And one thing that is not reasonable: deciding anything about your own medication on the basis of a research headline, including this article.

Where a Retreat Fits — and Where It Does Not

Directly: The Pearl Laguna Beach does not treat depression. We are a twelve-room wellness retreat in Laguna Beach, California, not a clinical facility, and nothing in our programme substitutes for assessment and treatment by a qualified professional.

What a structured week can do is supply several of the things in the list above at once — protected sleep, daily movement without performance pressure, meals without planning, and a period with the daily load genuinely removed. Those are supportive, they are modest, and for someone in active treatment they sit alongside that treatment rather than in place of it.

If the low mood has not lifted in weeks, or does not lift when you are away from work and ordinary demands, that is a reason to see a physician rather than to book a week away. We go through that distinction in burnout versus depression.

Frequently Asked Questions

Is depression caused by a chemical imbalance?

There is no good evidence for a simple chemical imbalance. A 2022 umbrella review in Molecular Psychiatry examined serotonin levels, receptor binding, transporter studies, tryptophan depletion and genetics, and found no consistent association between serotonin and depression. That review was contested in detail by 36 researchers, so the scientific question is not settled — but the popular version, that depression is a measurable deficiency of one brain chemical, was always a simplification of a hypothesis rather than an established finding.

Does this mean antidepressants don't work?

No, and this is the most common misreading. Whether a drug works is tested by randomised trials, not by theories about mechanism. A network meta-analysis of 522 trials and 116,477 participants found all 21 antidepressants studied were more likely than placebo to produce a response at eight weeks, with odds ratios between 1.37 and 2.13. The authors described the effects as modest and noted that many trials carried some risk of bias — real and limited, not absent.

Should I stop taking my antidepressant?

Not because of anything you read in the news, and not without speaking to the clinician who prescribed it. Stopping abruptly can cause withdrawal symptoms that are sometimes prolonged, and there is a relapse risk to weigh. If you want to reduce or stop, that is a legitimate conversation to have with your prescriber, who can plan a taper.

What actually causes depression then?

Current models are multifactorial. Prolonged stress, disrupted sleep, low-grade inflammation in a subgroup, highly polygenic genetic risk, and circumstances such as isolation, poverty or chronic illness all contribute, and they interact. Depression looks less like one disease with one broken part than like a common endpoint several different routes arrive at, which is part of why two people with the same diagnosis can need different things.

Is depression caused by inflammation?

For some people inflammation appears to be part of it. A meta-analysis of 37 studies found 27% of people with depression had CRP above 3 mg/L and 58% above 1 mg/L, with higher odds than matched controls. That is a substantial subgroup rather than everyone, the direction of causation is unresolved, and trials of anti-inflammatory treatment have given mixed results. It does not support treating depression as an inflammatory disease.

Can lifestyle changes treat depression?

They can help and they are not a replacement for treatment in moderate or severe depression. Exercise has the strongest evidence of any lifestyle intervention — a BMJ network meta-analysis of 218 trials found walking, jogging, yoga and strength training all effective for depressive symptoms. Protecting sleep is the other high-value lever. Both are worth doing alongside clinical care rather than instead of it.

Why does it matter which explanation is right?

Because the explanation changes behaviour. Believing in a permanent chemical deficiency makes people reason differently about starting and continuing medication, and may contribute to very long-term use. Concluding from a headline that depression is "not biological" can equally lead someone to discount treatments that would help. The accurate version — multiple contributing routes, several effective treatments, some modifiable factors — supports better decisions than either extreme.